Table 2.
Clinical, endoscopic, and histological data in patients with EoE before and after a 6-week treatment with orodispersible budesonide tablets.
| EoE Patients at Baseline (n = 14) |
EoE Patients Post Treatment (n = 14) |
p | |
|---|---|---|---|
| Straumann Dysphagia Index; median (IQR) | 9 (3–13) | 1 (1–6) | <0.001 |
| Esophageal dilation; n | 2 | 0 | 0.241 |
| EEsAI-PRO score; mean ± SD (range) | 49 ± 28 (15–80) | 12 ± 25 (0–42) | <0.001 |
| EREFS score; median (IQR) | 4 (2–8) | 0 (0–4) | <0.001 |
| Edema; n | <0.001 | ||
| 0: Distinct vascularity | 1 | 13 | |
| 1: Decreased | 13 | 1 | |
| 2: Absent | 0 | 0 | |
| Rings; n | 0.384 | ||
| 0: None | 9 | 10 | |
| 1: Mild | 1 | 3 | |
| 2: Moderate | 3 | 1 | |
| 3: Severe | 1 | 0 | |
| Exudates; n | <0.001 | ||
| 0: None | 1 | 13 | |
| 1: Mild | 3 | 1 | |
| 2: Severe | 10 | 0 | |
| Furrows; n | <0.001 | ||
| 0: None | 0 | 13 | |
| 1: Mild | 14 | 1 | |
| 2: Severe | 0 | 0 | |
| Strictures; n | 0.049 | ||
| 0: Absent | 10 | 14 | |
| 1: Present | 4 | 0 | |
| Crêpe paper; n | 0.241 | ||
| 0: Absent | 12 | 14 | |
| 1: Present | 2 | 0 | |
| Peak eosinophil count at proximal esophagus, cells/high power field; median (IQR) | 40 (17–120) | 0 (0–5) | <0.001 |
| Peak eosinophilic count at distal esophagus, cells/high power field; median (IQR) | 53 (28–100) | 0 (0–16) | <0.001 |
| Discomfort after EndoFLIPTM; n | 1 | 0 | 0.5 |
IQR, interquartile range; EesAI-PRO, eosinophilic esophagitis activity index—patient-reported outcome; EoE, eosinophilic esophagitis, EREFS, endoscopic reference score, EndoFLIPTM, endoscopic functional lumen imaging probe.